human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
Award Notice Posted
- Solicitation number
- HT9425-25-D-0009
- Agency
-
Defense Health Agency
Department of Defense
- Awarded
- to Mapp Biopharmaceutical, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT9425-25-D-0009 Federal IDV award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- San Diego, California 92121, United States
Notice details come from SAM.gov. Updated .
About this opportunity
Mapp Biopharmaceutical, Inc. has been awarded a Firm Fixed Price Sole Source Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the Defense Health Agency for the delivery of human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags) in support of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). The contract, identified as HT9425-25-D-0009, was awarded on May 29, 2025, with a total value of $2,000,000. This contract will facilitate the procurement of specialized biological research materials, specifically focused on antibodies and antigens that are critical for infectious disease research and potential medical countermeasure development.
Notice text
Mapp Biopharmaceutical, Inc. received a Firm Fix Price Sole Source IDIQ award for the delivery of human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags) in support of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).
Awarded contract HT9425-25-D-0009 to MAPP BIOPHARMACEUTICAL, INC. for 2000000.00 on 2025-05-29.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity